81290-45-1

Basic information

• Product Name: 2-(PIPERIDIN-3-YL)-ACETIC ACID ETHYL ESTER
• Synonyms: PIPERIDIN-3-YL-ACETIC ACID ETHYL ESTER
• CAS NO: 81290-45-1
• Molecular Formula: C₉H₁₇NO₂
• Molecular Weight: 171.24
• Mol File: 81290-45-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 232.8 °C at 760 mmHg
• Flash Point: 94.6 °C
• Appearance: /
• Density: 0.969 g/cm³
• CAS DataBase Reference: 2-(PIPERIDIN-3-YL)-ACETIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(PIPERIDIN-3-YL)-ACETIC ACID ETHYL ESTER(81290-45-1)
• EPA Substance Registry System: 2-(PIPERIDIN-3-YL)-ACETIC ACID ETHYL ESTER(81290-45-1)

Safety Data

• Hazardous Substances Data: 81290-45-1(Hazardous Substances Data)

Usage

General Description

2-(Piperidin-3-yl)-acetic acid ethyl ester is a chemical compound with the molecular formula C11H19NO2. It is an ester derivative of a piperidine-based acetic acid, and its compound is commonly used in medical and pharmaceutical research. This particular chemical structure has been identified as a potential inhibitor of a specific enzyme, making it a potentially important compound for drug discovery and development. Additionally, it has shown promise in the treatment of certain neurological and psychiatric disorders, demonstrating its potential as a therapeutic agent. The ester form of the compound allows for easy administration and absorption in the body, making it a useful and versatile tool in the study and development of new medications.

Upstream product

• 39931-77-6 pyridin-3-yl-acetic acid ethyl ester 
• 611-71-2 MANDELIC ACID 
• 1232140-16-7 1-benzyl-3-ethoxycarbonylmethyl-pyridinium chloride 
• 3423-47-0 3-(2-ethoxy-2-oxoethyl)pyridin-1-ium-1-olate 
• 6419-36-9 3-pyridineacetic acid hydrochloride 

Downstream Products

• 953079-96-4 3-ethoxycarbonylmethyl-piperidine-1-carboxylic acid benzyl ester 
• 953080-30-3 (1-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxypyrimidin-4-yl)piperidin-3-yl)acetic acid ethyl ester 
• 384830-13-1 (3'R) ethyl 2-[N-(t-butoxycarbonyl)piperidin-3-yl]acetate 
• 188883-58-1 ethyl (S)-2-(piperidin-3-yl)acetate 
• 1334404-24-8 (S)-(1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 1334404-25-9 (R)-(1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 1334404-29-3 C₂₃H₂₉F₃N₄O₄ 
• 1334404-23-7 (1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid 
• 193629-24-2 ethyl (S)-2-(piperidin-3-yl)acetate (D)-mandelate 
• 1334404-28-2 (1-{2-methoxy-6-[2-(4-trifluoromethoxy-phenyl)-ethylamino]-pyrimidin-4-yl}-piperidin-3-yl)-acetic acid ethyl ester 
• 188883-57-0 ethyl (3R)-piperidin-3-ylacetate 

Relevant articles and documents

Practical and scalable synthesis of ethyl (R)-piperidine-3-acetate

A practical and scalable synthesis of ethyl (R)-piperidine-3-acetate was achieved from commercially available 3-pyridylacetic acid in 76% overall yield. The practical synthesis was demonstrated on 100-g scale. One-pot reductive N-ethylation of the pyridinium salt with acetonitrile gave an N-ethyl piperidine derivative. Copyright Taylor & Francis Group, LLC.

Microwave-assisted hydrogenation of pyridines

Using a commercially available device for controlled introduction of hydrogen in a vial for reactions under microwave dielectric heating, we developed a protocol for the transformation of substituted pyridines into the corresponding piperidines. Complete reduction occurred in 40 minutes, or even less, on substrates that require 24-48 hours to be reduced under standard conditions. Moreover, the reduction proved to be as stereoselective as the corresponding reaction carried out at room temperature. Georg Thieme Verlag Stuttgart.

2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a compound of formula (I) wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound of the invention.